Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium
Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Annals of Pediatric Cardiology |
| Subjects: | |
| Online Access: | http://www.annalspc.com/article.asp?issn=0974-2069;year=2020;volume=13;issue=4;spage=334;epage=336;aulast=Arya |
| _version_ | 1818550884706025472 |
|---|---|
| author | Adhi Arya Sushil Azad Radhakrishnan Sitaraman |
| author_facet | Adhi Arya Sushil Azad Radhakrishnan Sitaraman |
| author_sort | Adhi Arya |
| collection | DOAJ |
| description | Heart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients. |
| first_indexed | 2024-12-12T08:52:29Z |
| format | Article |
| id | doaj.art-0d20ce97428647bc8eeb0f96a5e0067f |
| institution | Directory Open Access Journal |
| issn | 0974-2069 |
| language | English |
| last_indexed | 2024-12-12T08:52:29Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Pediatric Cardiology |
| spelling | doaj.art-0d20ce97428647bc8eeb0f96a5e0067f2022-12-22T00:30:09ZengWolters Kluwer Medknow PublicationsAnnals of Pediatric Cardiology0974-20692020-01-0113433433610.4103/apc.APC_9_20Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentariumAdhi AryaSushil AzadRadhakrishnan SitaramanHeart failure due to congenital heart disease and cardiomyopathies is a significant burden in the pediatric population. Pharmacological strategies for the management of pediatric heart failure are largely based on the extrapolation of adult data and Delphi process based on expert opinion. There are differences in the etiology, clinical course, and outcome of pediatric heart failure as compared to adult, thus the results of adult heart failure trials cannot be simply extrapolated to pediatric patients. There have been a lot of newer drugs for adults with heart failure, but there is a void for pediatric population with heart failure due to many reasons. Early results of multi-centric randomized control PANORAMA HF Trial and subsequent Food and Drug Administration approval for Angiotensin Receptor and Neprylisin Inhibitor (Sacubitril / Valsartan) for pediatric patients have tried to fill in this void and paved the way for a newer class of drugs for heart failure with proven benefits in pediatric patients.http://www.annalspc.com/article.asp?issn=0974-2069;year=2020;volume=13;issue=4;spage=334;epage=336;aulast=Aryaarniheart failurepediatricsacubitril-valsartan |
| spellingShingle | Adhi Arya Sushil Azad Radhakrishnan Sitaraman Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium Annals of Pediatric Cardiology arni heart failure pediatric sacubitril-valsartan |
| title | Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium |
| title_full | Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium |
| title_fullStr | Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium |
| title_full_unstemmed | Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium |
| title_short | Angiotensin receptor and neprylisin inhibitor: A new drug in pediatric cardiologist's armamentarium |
| title_sort | angiotensin receptor and neprylisin inhibitor a new drug in pediatric cardiologist s armamentarium |
| topic | arni heart failure pediatric sacubitril-valsartan |
| url | http://www.annalspc.com/article.asp?issn=0974-2069;year=2020;volume=13;issue=4;spage=334;epage=336;aulast=Arya |
| work_keys_str_mv | AT adhiarya angiotensinreceptorandneprylisininhibitoranewdruginpediatriccardiologistsarmamentarium AT sushilazad angiotensinreceptorandneprylisininhibitoranewdruginpediatriccardiologistsarmamentarium AT radhakrishnansitaraman angiotensinreceptorandneprylisininhibitoranewdruginpediatriccardiologistsarmamentarium |